Patheon N.V. (NYSE:PTHN) Files An 8-K Submission of Matters to a Vote of Security Holders

Patheon N.V. (NYSE:PTHN) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item 5.07> Submission of Matters to a Vote of Security
Holders.

The following matters were voted upon and adopted at the 2017
Annual Meeting of Shareholders of Patheon N.V. (the “Company”)
held on March 7, 2017:
1.Appointment of the following persons as directors of our Board:

Nominee
For
Against
Abstain
Broker Non-Votes
(1a)
James C. Mullen
134,850,968
6,398,027
37,875
503,364
(1b)
Stephan B. Tanda
134,321,524
6,927,471
37,875
503,364
(1c)
Jeffrey P. McMullen
130,706,987
10,541,923
37,960
503,364
(1d)
Gary P. Pisano
134,469,958
6,778,941
37,971
503,364
(1e)
Charles I. Cogut
133,994,909
7,254,001
37,960
503,364
2. Approval, by non-binding vote, of the compensation of the
Company’s named executive officers.

For
136,604,794
Against
4,646,141
Abstain
35,935
Broker Non-Votes
503,364
3. Approval, by non-binding vote, of the frequency of the advisory
vote on executive compensation.

1 year
141,050,520
2 years
5,726
3 years
195,012
Abstain
35,612
Broker Non-Votes
503,364
4. Approval of the adoption of the financial statements for the
fiscal year 2016.

For
141,550,260
Against
Abstain
239,674
Broker Non-Votes
5. Discharge from liability of the members of our Board of
Directors in respect of the exercise of their duties for the fiscal
year 2016.

For
141,211,975
Against
37,323
Abstain
37,572
Broker Non-Votes
503,364
6. Appointment of Ernst Young LLP as the Company’s independent
registered public accounting firm and our statutory auditor for
the fiscal year ending October 31, 2017.

For
141,733,371
Against
21,516
Abstain
35,347
Broker Non-Votes
7. Re-authorization of our Board of Directors to acquire shares
in the Company’s own capital until September 7, 2018.

For
127,548,666
Against
14,221,795
Abstain
19,773
Broker Non-Votes
8. Re-authorization of our Board of Directors to grant or issue
(rights to acquire) shares until March 7, 2022.

For
129,168,278
Against
12,604,679
Abstain
17,277
Broker Non-Votes
9. Re-authorization of our Board of Directors to limit or exclude
preemptive rights in respect of a grant or issue of (rights to
acquire) shares.

For
128,950,523
Against
12,335,456
Abstain
Broker Non-Votes
503,364
10. Authorization of an amendment to the Company’s 2016 Omnibus
Incentive Plan.

For
131,111,408
Against
10,139,069
Abstain
36,393
Broker Non-Votes
503,364


About Patheon N.V.> (NYSE:PTHN)

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Patheon N.V.> (NYSE:PTHN) Recent Trading Information

Patheon N.V.> (NYSE:PTHN) closed its last trading session down -0.01 at 30.94 with 230,616 shares trading hands.

An ad to help with our costs